A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.

Saved in:
Bibliographic Details
Title: A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.
Authors: Ku G; Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, New York, New York., Shen L; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China., Dayyani F; University of California Irvine Chao Family Comprehensive Cancer Center, Orange, California., Kratz J; University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin., Liang X; Hubei Cancer Hospital, Wuhan, China., Liu F; The First Hospital of China Medical University, Shenyang, China., Wang Z; The First Hospital of China Medical University, Shenyang, China., Feller L; Horizon BioAdvance, Lafayette, Indiana., Girda E; Rutgers Cancer Institute, New Brunswick, New Jersey., Pan H; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China., Kim S; University of Colorado Cancer Center, Aurora, Colorado., Deng Y; The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Deng T; Tianjin Cancer Hospital, Tianjin, China., Liu T; Zhongshan Hospital, Fudan University, Shanghai, China., Powderly J; Carolina BioOncology Institute, Huntersville, North Carolina., Spencer K; Perlmutter Cancer Center of NYU Langone Health & NYU Grossman School of Medicine, New York, New York., Schneider R; Mary Crowley Cancer Research Center, Dallas, Texas., Berlin J; Vanderbilt University Medical Center, Nashville, Tennessee., Xu CC; I-Mab Biopharma, Rockville, Maryland., Ahlers CM; I-Mab Biopharma, Rockville, Maryland., Liu X; I-Mab Biopharma, Rockville, Maryland., Chung JK; I-Mab Biopharma, Rockville, Maryland., Sabbatini P; I-Mab Biopharma, Rockville, Maryland., Park J; ABL Bio Inc., Seongnam, Republic of Korea., Lim Y; ABL Bio Inc., Seongnam, Republic of Korea., Jeon J; ABL Bio Inc., Seongnam, Republic of Korea., Meng Y; TJ Biopharma, Hangzhou, China., Klempner SJ; Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Dec 01; Vol. 31 (23), pp. 4944-4952.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-24-4280